Clinical characteristics
| . | . | Below . | Equal . | Above . | Total . | P . |
|---|---|---|---|---|---|---|
| Number | Total | 4.8% | 63.4% | 31.8% | 100.0% | |
| Sex | Male | 60.0% | 53.2% | 50.0% | 52.5% | .65 |
| Female | 40.0% | 46.8% | 50.0% | 47.5% | ||
| Age | Minimum | 28.94 | 4.61 | 17.39 | 5.00 | |
| Maximum | 81.70 | 87.23 | 84.31 | 87.00 | ||
| Median | 68.72 | 64.60 | 63.31 | 64.60 | ||
| SD | 11.40 | 15.84 | 14.58 | 15.26 | ||
| French-American-British classification | M0 | 5.0% | 4.2% | 6.8% | 5.1% | |
| M1 | 5.0% | 9.1% | 17.4% | 11.6% | ||
| M2 | 25.0% | 39.9% | 32.6% | 36.9% | ||
| M4 | 15.0% | 19.8% | 22.0% | 20.2% | ||
| M4Eos | 0.0% | 4.6% | 0.8% | 3.1% | ||
| M5 | 5.0% | 6.8% | 16.7% | 9.9% | ||
| M6 | 25.0% | 6.1% | 0.0% | 5.1% | ||
| M7 | 5.0% | 1.9% | 1.5% | 1.9% | ||
| RAEBT | 15.0% | 6.5% | 2.3% | 5.5% | ||
| World Health Organization 2008 classification | Inv16 | 0.0% | 6.1% | 2.3% | 4.6% | |
| t(8:21) | 5.0% | 3.4% | 3.0% | 3.4% | ||
| Chromosome 11 | 0.0% | 1.5% | 4.5% | 2.4% | ||
| TX Rel-Chemo&XRT | 0.0% | 4.2% | 5.3% | 4.3% | ||
| TX Rel XRT | 5.0% | 4.6% | 1.5% | 3.6% | ||
| Tx Rel Chemo | 0.0% | 6.8% | 2.3% | 5.1% | ||
| PriorMDS-MPD | 30.0% | 21.3% | 12.1% | 18.8% | ||
| Not in other | 60.0% | 52.1% | 68.9% | 57.8% | ||
| Zubrod performance status | 0-1 | 85.0% | 80.6% | 81.1% | 81.0% | .82 |
| 2 | 15.0% | 15.2% | 16.7% | 15.7% | ||
| 3 or 4 | 0.0% | 3.8% | 2.3% | 3.1% | ||
| Antecedent hematological disorder ≥ 2 mo | No | 65.0% | 56.7% | 74.2% | 62.7% | .002 |
| Yes | 35.0% | 43.3% | 25.0% | 37.1% | ||
| Infection | No | 90.0% | 81.4% | 68.9% | 77.8% | .008 |
| Yes | 10.0% | 18.6% | 31.1% | 22.2% | ||
| Cytogenetics | t8;21 | 5.0% | 3.4% | 3.0% | 3.4% | |
| inv16 | 0.0% | 6.1% | 2.3% | 4.6% | ||
| diploid | 40.0% | 41.1% | 46.2% | 42.7% | ||
| IM | 0.0% | 1.5% | 2.3% | 1.7% | ||
| −5 | 15.0% | 3.8% | 4.5% | 4.6% | ||
| −5, −7 | 5.0% | 5.3% | 1.5% | 4.1% | ||
| −7 | 10.0% | 6.8% | 5.3% | 6.5% | ||
| −7, +8 | 0.0% | 1.1% | 0.0% | 0.7% | ||
| −5, −7, +8 | 5.0% | 0.8% | 2.3% | 1.4% | ||
| 8 | 5.0% | 8.4% | 3.8% | 6.7% | ||
| 11q23 | 0.0% | 1.5% | 4.5% | 2.4% | ||
| 21 | 0.0% | 1.5% | 0.8% | 1.2% | ||
| t6;9 | 5.0% | 0.8% | 2.3% | 1.4% | ||
| inv9 | 0.0% | 0.8% | 0.0% | 0.5% | ||
| t9;22 | 5.0% | 0.0% | 0.0% | 0.2% | ||
| FLT3 mutation | No | 65.0% | 81.4% | 65.2% | 75.4% | 5 × 10-08 |
| Yes | 30.0% | 14.4% | 33.3% | 21.2% | ||
| Ras mutation | Yes | 11.8% | 12.6% | 12.6% | 14.3% | .99 |
| No | 88.2% | 87.4% | 87.4% | 85.7% | ||
| Response | CR | 65.0% | 58.6% | 53.0% | 57.1% | .44 |
| Resistance | 20.0% | 31.6% | 37.1% | 32.8% | ||
| Fail | 15.0% | 9.9% | 9.8% | 10.1% | ||
| Relapse | Yes | 84.6% | 58.4% | 64.3% | 61.6% | .15 |
| Alive | Yes | 10.0% | 29.7% | 20.5% | 25.8% | .036 |
| No | 90.0% | 70.3% | 79.5% | 74.2% | ||
| Remission duration, median, wk | 22.57 | 48.78 | 40.57 | 44.14 | .05 | |
| Median survival, wk | 45.21 | 58.00 | 35.35 | 48.71 | .03 |
| . | . | Below . | Equal . | Above . | Total . | P . |
|---|---|---|---|---|---|---|
| Number | Total | 4.8% | 63.4% | 31.8% | 100.0% | |
| Sex | Male | 60.0% | 53.2% | 50.0% | 52.5% | .65 |
| Female | 40.0% | 46.8% | 50.0% | 47.5% | ||
| Age | Minimum | 28.94 | 4.61 | 17.39 | 5.00 | |
| Maximum | 81.70 | 87.23 | 84.31 | 87.00 | ||
| Median | 68.72 | 64.60 | 63.31 | 64.60 | ||
| SD | 11.40 | 15.84 | 14.58 | 15.26 | ||
| French-American-British classification | M0 | 5.0% | 4.2% | 6.8% | 5.1% | |
| M1 | 5.0% | 9.1% | 17.4% | 11.6% | ||
| M2 | 25.0% | 39.9% | 32.6% | 36.9% | ||
| M4 | 15.0% | 19.8% | 22.0% | 20.2% | ||
| M4Eos | 0.0% | 4.6% | 0.8% | 3.1% | ||
| M5 | 5.0% | 6.8% | 16.7% | 9.9% | ||
| M6 | 25.0% | 6.1% | 0.0% | 5.1% | ||
| M7 | 5.0% | 1.9% | 1.5% | 1.9% | ||
| RAEBT | 15.0% | 6.5% | 2.3% | 5.5% | ||
| World Health Organization 2008 classification | Inv16 | 0.0% | 6.1% | 2.3% | 4.6% | |
| t(8:21) | 5.0% | 3.4% | 3.0% | 3.4% | ||
| Chromosome 11 | 0.0% | 1.5% | 4.5% | 2.4% | ||
| TX Rel-Chemo&XRT | 0.0% | 4.2% | 5.3% | 4.3% | ||
| TX Rel XRT | 5.0% | 4.6% | 1.5% | 3.6% | ||
| Tx Rel Chemo | 0.0% | 6.8% | 2.3% | 5.1% | ||
| PriorMDS-MPD | 30.0% | 21.3% | 12.1% | 18.8% | ||
| Not in other | 60.0% | 52.1% | 68.9% | 57.8% | ||
| Zubrod performance status | 0-1 | 85.0% | 80.6% | 81.1% | 81.0% | .82 |
| 2 | 15.0% | 15.2% | 16.7% | 15.7% | ||
| 3 or 4 | 0.0% | 3.8% | 2.3% | 3.1% | ||
| Antecedent hematological disorder ≥ 2 mo | No | 65.0% | 56.7% | 74.2% | 62.7% | .002 |
| Yes | 35.0% | 43.3% | 25.0% | 37.1% | ||
| Infection | No | 90.0% | 81.4% | 68.9% | 77.8% | .008 |
| Yes | 10.0% | 18.6% | 31.1% | 22.2% | ||
| Cytogenetics | t8;21 | 5.0% | 3.4% | 3.0% | 3.4% | |
| inv16 | 0.0% | 6.1% | 2.3% | 4.6% | ||
| diploid | 40.0% | 41.1% | 46.2% | 42.7% | ||
| IM | 0.0% | 1.5% | 2.3% | 1.7% | ||
| −5 | 15.0% | 3.8% | 4.5% | 4.6% | ||
| −5, −7 | 5.0% | 5.3% | 1.5% | 4.1% | ||
| −7 | 10.0% | 6.8% | 5.3% | 6.5% | ||
| −7, +8 | 0.0% | 1.1% | 0.0% | 0.7% | ||
| −5, −7, +8 | 5.0% | 0.8% | 2.3% | 1.4% | ||
| 8 | 5.0% | 8.4% | 3.8% | 6.7% | ||
| 11q23 | 0.0% | 1.5% | 4.5% | 2.4% | ||
| 21 | 0.0% | 1.5% | 0.8% | 1.2% | ||
| t6;9 | 5.0% | 0.8% | 2.3% | 1.4% | ||
| inv9 | 0.0% | 0.8% | 0.0% | 0.5% | ||
| t9;22 | 5.0% | 0.0% | 0.0% | 0.2% | ||
| FLT3 mutation | No | 65.0% | 81.4% | 65.2% | 75.4% | 5 × 10-08 |
| Yes | 30.0% | 14.4% | 33.3% | 21.2% | ||
| Ras mutation | Yes | 11.8% | 12.6% | 12.6% | 14.3% | .99 |
| No | 88.2% | 87.4% | 87.4% | 85.7% | ||
| Response | CR | 65.0% | 58.6% | 53.0% | 57.1% | .44 |
| Resistance | 20.0% | 31.6% | 37.1% | 32.8% | ||
| Fail | 15.0% | 9.9% | 9.8% | 10.1% | ||
| Relapse | Yes | 84.6% | 58.4% | 64.3% | 61.6% | .15 |
| Alive | Yes | 10.0% | 29.7% | 20.5% | 25.8% | .036 |
| No | 90.0% | 70.3% | 79.5% | 74.2% | ||
| Remission duration, median, wk | 22.57 | 48.78 | 40.57 | 44.14 | .05 | |
| Median survival, wk | 45.21 | 58.00 | 35.35 | 48.71 | .03 |
The clinical characteristics of the total population and of patients with FLI1 expression below, equal to, or above that of normal CD34+ cells is shown.